Insulin resistance and sympathetic overactivity in women

Journal of Hypertension

Volumn 24, Issue 1, 2006, Pages 131-141

  Kaaja, Risto J ^a   Pöyhönen Alho, Maritta K ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Antihypertensive drugs; Insulin resistance; Norepinephrine; Postmenopausal hypertension; Pre eclampsia; Renin angiotensin system; Sympathetic activity

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLITAZONE DERIVATIVE; INSULIN; METFORMIN; MOXONIDINE;

AGING; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIET THERAPY; DISEASE ASSOCIATION; DRUG USE; FEMALE; GLUCOSE TOLERANCE; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; KINESIOTHERAPY; LIFESTYLE; MENARCHE; MENOPAUSE; METABOLIC SYNDROME X; OBESITY; OVARY POLYCYSTIC DISEASE; POSTMENOPAUSE; PREECLAMPSIA; PREGNANCY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYMPATHETIC FUNCTION; SYMPATHETIC TONE;

EID: 29144474608     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000194121.19851.e5     Document Type: Review

References (123)

1. Lindgren F, Dahlqvist S, Efendic S, Persson B, Skottner A. Insulin sensitivity and glucose-induced insulin response changes during adolescence. Acta Paediatr Scand 1990; 79:431-436.
2. Kaaja R, Laivuori H, Laakso M, Tikkanen MJ, Ylikorkala O. Evidence of a state of increased insulin resistance in preeclampsia. Metabolism 1999; 48:892-896.
3. Reaven GM. Role of insulin resistance in human disease (syndrome X): an expanded definition. Ann Rev Med 1993; 44:121-131.
4. Wilson PW, Kannel WB, Silbershatz H, D'Agostino RB. Clustering of metabolic factors and coronary artery disease. Arch Intern Med 1999; 159:1104-1109.
5. Brook RD, Julius S. Autonomic imbalance, hypertension and cardiovascular risk. Am J Hypertens 2000; 13:112S-122S.
6. Grassi G, Vailati S, Bertinieri G, Seravalle G, Stella ML, Dell'Oro R, Mancia G. Heart rate as marker of sympathetic activity. J Hypertens 1998; 16:1635-1639.
7. Grassi M, Esler M. How to assess sympathetic activity in humans. J Hypertens 1999; 17:719-734.
8. Eckberg DL. Sympathovagal balance: a critical appraisal. Circulation 1997; 96:3224-3232.
9. Godsland IF. The minimal model: an evolving methodology. Clin Sci 2003; 105:531-532.
10. Matsuda M, DeFronzo R. Insulin sensitivity indices obtained from oral glucose tolerance testing. Comparison with euglycemic insulin clamp. Diabetes Care 1999; 22:1462-1470.
11. Del Prato S, Pozilli P. FIRI: fasting or false insulin resistance index? Lancet 1996; 347:132.
12. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ. Quantitative insulin sensitivity check index. A simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000; 85:2402-2410.
13. Perseghin G, Caumo A, Caloni M, Testolin G, Luzi L. Incorporation of the fasting plasma FFA concentration into QUICKI improves its association with insulin sensitivity in nonobese individuals. J Clin Endocrinol Metab 2001; 86:4776-4781.
14. Soonthornpurn S, Setasuban W, Thamprasit A, Chayanunnukul W. Novel insulin sensitivity index derived from oral glucose tolerance test. J Clin Endocrinol Metab 2003; 88:1019-1023.
15. Yokoyama H, Emoto M, Fujiwara S, Motoyama K, Morioka T, Komatsu M, et al. Quantitative insulin sensitivity check index and the reciprocal index of homeostasis model assessment in normal range weight and moderately obese type 2 diabetic patients. Diabetes Care 2003; 26:2426-2432.
16. 6 Livingstone C, Collison M. Sex steroids and insulin resistance. Clin Sci 2002; 102:151-166.
17. Ryan EA. Hormones and insulin resistance during pregnancy. Lancet 2003; 362:1777-1778.
18. Kaaja R, Tikkanen M, Viinikka L, Ylikorkala O. Serum lipoproteins, insulin and urinary excretion of prostanoid metabolites in normal and hypertensive pregnant women. Obstet Gyn 1995; 85:353-356.
19. Agardh CD, Åberg A, Norden NE. Glucose levels and insulin secretion during a 75g glucose challenge test in normal pregnancy. J Intern Med 1996; 240:303-309.
20. Seely EW, Carrol JA, Goodfriend TL, Tao QF, Graves W. Digitalis-like factor response to hyperinsulinemia in human pregnancy, a model of insulin resistance. J Hum Hypertens 2002; 16:851-856.
21. Chen X, Scholl TO, Leskiw MJ, Donaldson MR, Stein TP. Association of glutathione peroxidase activity with insulin resistance and dietary fat intake during normal pregnancy. J Clin Endocrinol Metab 2003; 88:5963-5968.
22. Kirwan JP, Varastehpour A, Jing M, Presley L, Shao J, Friedman JE, Catalano PM. Reversal of insulin resistance postpartum is linked to enhanced skeletal muscle insulin signaling. J Clin Endocrinol Metab 2004; 89:4678-4684.
23. Sivan E, Chen X, Homko CJ, Reece EA, Boden G. Longitudinal study of carbohydrate metabolism in healthy obese pregnant women. Diabetes Care 1997; 20:1470-1475.
24. Buchanan TA, Metzger BE, Freinkel N, Bergman RN. Insulin sensitivity and B-cell responsiveness to glucose during late pregnancy in lean and moderately obese women in normal glucose tolerance or mild gestational diabetes. Am J Obstet Gynecol 1990; 162:1008-1014.
25. Kirwan JP, Hauguel-De Mouzon S, Lepercq J, Challier J-C, Huston-Presley L, Friedman JE, et al. TNF-[alpha] is a predictor of insulin resistance in human pregnancy. Diabetes 2002; 51:2207-2213.
26. Catalano PM, Drago NM, Amini SB. Longitudinal changes in pancreatic beta-cell function and metabolic clearance rate of insulin in pregnant women with normal and abnormal glucose tolerance. Diabetes Care 1998; 21:403-408.
27. Kautzky-Willer A, Prager R, Waldhausl W, Pacini G, Thomaseth K, Wagner OF, et al. Pronounced insulin resistance and inadequate beta-cell secretion characterize lean gestational diabetes during and after pregnancy. Diabetes Care 1997; 20:1717-1723.
28. Seely EW, Solomon CG. Insulin resistance and its potential role in pregnancy-induced hypertension. Hypertension 2003; 88:2393-2398.
29. Schobel HP, Fischer T, Heusser K, Geiger H, Schmieder RE. Preeclampsia - a state of sympathetic overactivity. N Engl J Med 1996; 335:1480-1485.
30. Yang C, Chao T-C, Kuo T, Yin C-S, Chen H. Preeclamptic pregnancy is associated with increased sympathetic and decreased parasympathetic control of HR. Am J Physiol Heart Circ Physiol 2000; 278:H1269-H1273.
31. Kaaja R, Moore P, Yandle T, Ylikorkala O, Frampton C, Nicholls G. Diurnal patterns of vasoactive hormones in early stage of pre-eclampsia. Hypertens Pregn 1999; 18:173-187.
32. Kaaja R, Leinonen A, Moore P, Yandle T, Frampton CM, Nicholls MG. Effect of changes in body posture on vasoactive hormones in preeclamptic women. J Hum Hypertens 2004; 18:789-794.
33. Antonazzo P, Cetin I, Tarricone D, Lombardi F, Pradi G. Cardiac autonomic modulation in normal, high-risk, and in vitro fertilization pregnancies during the first trimester. Am J Obstet Gynecol 2004; 190:199-205.
34. Greenwood JP, Stoker JB, Walker JJ, Mary D. Sympathetic nerve discharge in normal pregnancy and pregnancy-induced hypertension. J Hypertens 1998; 16:617-624.
35. Greenwood JP, Scott E, Stoker JB, Walker JJ, Mary D. Sympathetic neural mechanisms in normal and hypertensive pregnancy in humans. Circulation 2001; 104:2200-2204.
36. Rang S, Wolf H, Montfrans G, Karemaker J. Serial assessment of cardiovascular control shows early signs of developing pre-eclampsia. J Hypertens 2004; 22:369-376.
37. Fischer T, Schobel H, Andereae M, Schneider K, Heusser K. Pregnancy-induced sympathetic overactivity: a precursor of preeclampsia. Eur J Clin Invest 2004; 34:443-448.
38. Voss A, Malberg H, Schumann A, Wesswl N, Walther T, Stepan H, Faber R. Baroreflex sensitivity, heart rate, and blood pressure variability in normal pregnancy. Am J Hypertens 2000; 13:1218-1225.
39. Faber A, Baumert M, Stepan H, Wessel N, Voss A, Walther T. Baroreflex sensitivity, heart rate, and blood pressure variability in hypertensive pregnancy disorders. J Hum Hypertens 2004; 18:707-712.
40. Avery ND, Wolfe LA, Amara CE, Davies GA, McGrath MJ. Effects of human pregnancy on cardiac autonomic function above and below the ventilatory threshold. J Appl Physiol 2001; 90:321-328.
41. Lucini D, Strappazzon P, Vecchia LD, Maggioni C, Pagani M. Cardiac autonomic adjustments to normal human pregnancy: insight from spectral analysis of R-R interval and systolic arterial pressure variability. J Hypertens 1999; 17:1899-1904.
42. Greer IA, Haddad NG, Dawes J, Johnstone FD, Calder AA. Neutrophil activation in pregnancy-induced hypertension. Br J Obstet Gynaecol 1989; 96:978-982.
43. Pradhan AD, Cook NR, Buring JE, Manson JAE, Ridker PM. C-reactive protein is independently associated with fasting insulin in nondiabetic women. Arterioscler Thromb Vasc Biol 2003; 23:650-655.
44. Dechend R, Fiebler A, Lindschau C, Bischoff H, Muller D, Park JK, et al. Modulating angiotensin II-induced inflammation by HMG Co-A reductase inhibition. Am J Hypertens 2001; 14:55S-61S.
45. Laivuori H, Tikkanen MJ, Ylikorkala O. Hyperinsulinemia 17 years after preeclamptic first pregnancy. J Clin Endocrinol Metab 1996; 81:2908-2911.
46. Laivuori H, Kaaja R, Rutanen E-M, Viinikka L, Ylikorkala O. Evidence of high circulating testosterone in women with prior preeclampsia. J Clin Endocrinol Metab 1998; 83:344-347.
47. He S, Silveira A, Hamsten A, Blomback M, Bremme K. Haemostatic, endothelial and lipoprotein parameters and blood pressure levels in women with history of preeclampsia. Thromb Haemost 1999; 81:538-542.
48. Chambers JC, Fusi L, Malik IS, Hskard DO, De Swiet M, Kooner JS. Association of maternal endothelial dysfunction with preeclampsia. JAMA 2001; 285:1607-1612.
49. Jonsdottir LS, Arngrimsson R, Geirsson RT, Sigvaldason H, Sigfusson N. Death rates from ischemic heart disease in women with a history of hypertension in pregnancy. Acta Obstet Gynecol Scand 1995; 74:772-776.
50. Sattar N, Greer I. Pregnancy complications and maternal cardiovascular risk. Opportunities for intervention and screening? BMJ 2002; 325:157-160.
51. Rodie V, Freeman DJ, Sattar N, Greer IA. Pre-eclampsia and cardiovascular disease: metabolic syndrome of pregnancy? Atherosclerosis 2004; 175:189-202.
52. Haukkamaa L, Salminen M, Laivuori H, Leinonen H, Hiilesmaa V, Kaaja R. Risk of subsequent coronary artery disease after preeclampsia. Am J Cardiol 2004; 93:805-808.
53. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Hum Reprod 2004; 19:41-47.
54. Ehrmann DA. Medical progress: Polycystic Ovary Syndrome. N Engl J Med 2005; 352:1223-1236.
55. Lara HE, Ferruz JL, Luza S, Bustamante DA, Borges Y, Ojeda SR. Activation of ovarian sympathetic nerves in polycystic ovary syndrome. Endocrinology 1993; 133:2690-2695.
56. Staessen J, Bulpitt CJ, Fagard R, Lijnen P, Amery A. The influence of menopause on blood pressure. J Hum Hypertens 1989; 3:427-433.
57. Crawford SL, Casey VA, Avis NE, McKinlay SM. A longitudinal study of weight and the menopause transition: results from the Massachusetts Women's Health Study. Menopause 2000; 7:96-104.
58. Toth MJ, Tchernof A, Sites CK, Poehlman ET. Effects of menopausal status on body composition and abdominal fat distribution. Int J Obes Relat Metab Disor 2000; 24:226-231.
59. Poehlman ET. Menopause, energy expenditure, and body composition. Acta Obstet Gyecol Scand 2002; 81:603-611.
60. Toth MJ, Sites CK, Eltabbakh GH, Poehlman ET. Effect of menopausal status on insulin-stimulated glucose disposal: comparison of middle-aged premenopausal and early postmenopausal women. Diabetes 2000; 23:801-806.
61. Lasco A, Alvaro S, Frisina N, Di Benedetto A, Denzzo G, Cucinotta D. Long-term transdermal estrogen therapy improves lipid profile but not insulin resistance in healthy postmenopausal women. Diabetes Care 2000; 23:422-424.
62. O'Shaughnessy IM, Kasdorf GM, Hoffmann RG, Kalkhoff RK. Does ageing intensify the insulin resistance of human obesity? J Clin Endocrinol Metab 1992; 74:1075-1081.
63. Lindheim SR, Buchanan TA, Duffy DM, Vijod MA, Kojima T, Stanczyk FZ, Lobo RA. Comparison of estimates of insulin sensitivity in pre- and postmenopausal women using the insulin tolerance test and the frequently sampled intravenous glucose tolerance test. Int Soc Gynecol Investig 1994; 1:150-154.
64. Walton C, Godsland IF, Proudler AJ, Wynn V, Stevenson JC. The effect of the menopause on insulin sensitivity, secretion and elimination in non-obese healthy women. Eur J Clin Invest 1993; 23:466-473.
65. Proudler AJ, Felton CV, Stevenson C. Ageing and the response of plasma insulin, glucose and C-peptide concentrations to intravenous glucose in postmenopausal women. Clin Sci 1992; 83:489-494.
66. Guthrie JR, Ball M, Dudley EC, Garamszegi CV, Wahlqvist ML, Dennerstein L, Burger HG. Impaired fasting glycaemia in middle-aged women: a prospective study. Int J Obes Relat Metab Disord 2001; 25:646-651.
67. DeNino WF, Tchernof A, Dionne IJ, Toth MJ, Ades PA, Sites CK, Poehlman ET. Contribution of abdominal adiposity to age-related differences in insulin sensitivity and plasma lipids in healthy nonobese women. Diabetes Care 2001; 24:925-932.
68. Liu CC, Kuo TBJ, Yang CCH. Effects of estrogen on gender-related autonomic differences in humans. Am J Physiol Heart Circ Physiol 2003; 285:H2188-H2193.
69. Deane R, Chummun H, Prashad D. Differences of urinary stress hormones in male and female nurses at different ages. J Adv Nurs 2002; 37:304-310.
70. Mercuro G, Longu G, Zoncu S, Cherchi A. Impaired forearm blood flow and vasodilator reserve in healthy postmenopausal women. Am Heart J 1999; 137:692-697.
71. Mercuro G, Podda A, Pitzalis L, Zoncu S, Mascia M, Melis GB, Rosano GM. Evidence of a role of endogenous estrogen in the modulation of autonomic nervous system. Am J Cardiol 2000; 85:787-789.
72. Rosano GM, Patrizi R, Leonardo F, Ponikowski P, Collins P, Sarrel PM, Chierchia SL. Effect of estrogen replacement therapy on heart rate variability and heart rate in healthy postmenopausal women. Am J Cardiol 1997; 80:815-817.
73. Weitz G, Elam M, Born J, Fehem HL, Dodt C. Postmenopausal estrogen administration suppresses muscle sympathetic nerve activity. J Clin Endocrinol Metab 2001; 86:344-348.
74. Narkiewicz K, Phillips BG, Kato M, Hering D, Bieniaszewski L, Somers VK. Gender-selective interaction between aging, blood pressure, and sympathetic nerve activity. Hypertension 2005; 45:522-525.
75. Esler M, Rumantir M, Wiesner G, Kaye D, Hastings J, Lambert G. Sympathetic nervous system and insulin resistance: From obesity to diabetes. Am J Hypertens 2001; 14:304S-309S.
76. Ng AV, Callister R, Johnson DG, Seals DR. Age and gender influence muscle sympathetic nerve activity at rest in healthy humans. Hypertension 1993; 21:498-503.
77. Matsuda T, Sugiyama Y, Watanabe T, Kobayashi F, Mano T. Gender difference in age-related changes in muscle sympathetic nerve activity in healthy subjects. Am J Physiol 1998; 275:R1600-R1604.
78. Grassi G, Seravalle G, Cattaneo BM, Bolla GB, Lanfranchi A, Colombo M, et al. Sympathetic activation in obese normotensive subjects. Hypertension 1995; 25:560-563.
79. Elhamdani A, Palfrey CH, Artalejo CR. Ageing changes the cellular basis of the 'fight-or-flight' response in human adrenal chromaffin cells. Neurobiol Aging 2002; 23:287-293.
80. Esler M, Lambert G, Kaye D, Rumantir M, Hastings J, Seals DR. Influence of ageing on the sympathetic nervous system and adrenal medulla at rest and during stress. Biogerontology 2002; 3:45-49.
81. Egan BM, Julius S. Role of sympathetic overactivity in the pathophysiology of the metabolic syndrome. Dialogues Cardiovasc Med 2004; 9:143-157.
82. Grassi G, Dell'Oro R, Facchini A, Quarti Trevano F, Bolla GB, Mancia G. Effect of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensives. J Hypertens 2004; 22:2363-2369.
83. Wisse BE. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. Front Nephrol 2004; 15:2792-2800.
84. Pfeilschifter J, Kodits R, Pfohl M, Schatz H. Changes in proinflammatory cytokine activity after menopause. Endocr Rev 2002; 23:90-119.
85. Grassi G. Leptin, sympathetic nervous sytem, and baroreflex function. Curr Hypertens Rep 2004; 6:236-240.
86. Considine RV, Sinha MK, Heiman ML. Serum immunoreactive leptin concentrations in normal-weight and obese humans. N Engl J Med 1996; 334:292-295.
87. Shek EW, Brands MW, Hall JE. Chronic leptin infusion increases arterial pressure. Hypertension 1998; 31:409-414.
88. Haynes WG, Morgan DA, Walsh SA. receptor-mediated regional sympathetic nerve activation by leptin. J Clin Invest 1997; 100:270-278.
89. Shamsuzzaman A, Winnicki M, Wolk R, Svatikova A, Phillips B, Davison D, et al. Independent association between plasma leptin and C-reactive protein in healthy humans. Circulation 2004; 109:2181-2185.
90. Nakanishi N, Shiraishi T, Wada M. C-reactive protein concentration is more strongly related to metabolic syndrome in women than in men: the Minoh study. Circ J 2005; 69:386-391.
91. Shamsuzzaman A, Gersh BJ, Somers VK. Obstructive sleep apnea: implications for cardiac and vascular disease. JAMA 2003; 290:1906-1914.
92. Grassi G, Facchini A, Trevano FQ, Dell'Oro R, Arenare F, Tana F, et al. Obstructive sleep apnea-dependent and -independent adrenergic activation in obesity. Hypertension 2005; 46:321-325.
93. Reckelhoff JF, Fortepiani LA. Novel mechanism responsible for postmenopausal hypertension. Hypertension 2004; 43:918-923.
94. Julius S, Jamerson K. Sympathetics, insulin resistance and coronary risk in hypertension; the chicken-and-egg question. J Hypertens 1994; 12:495-502.
95. Landsberg L. Diet, obesity and hypertension: an hypothesis involving insulin, the sympathetic nervous system, and adaptive thermogenesis. Q J Med 1986; 236:1081-1090.
96. Berne C, Fagius J, Pollare T, Hejmdahl P. The sympathetic response to euglycemic hyperinsulinemia: evidence for microelectrical nerve recording in healthy subjects. Diabetologia 1992; 38:873-879.
97. Rowe JW, Young JB, Minaker KL, Stevens AL, Pallotta J, Landsberg L. Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man. Diabetes 1981; 30:219-225.
98. Hausberg M, Mark AL, Hoffman RP, Sinkey CA, Andersson EA. Dissociation of sympathoexcitatory and vasodilator actions of modestly elevated plasma insulin levels. J Hypertens 1995; 13:1015-1021.
99. Diebert DC, DeFronzo RA. Epinephrine-induced insulin resistance in man. J Clin Invest 1980; 65:717-721.
100. Raz I, Katz A, Spencer MK. Epinephrine inhibits insulin-mediated glycogensis but enhances glycolysis in human skeletal muscle. Am J Physiol Endocrinol Metab 1991; 260:E430-E435.
101. Avogaro A, Toffolo G, Valerio A, Cobelli C. Epinephrine exerts opposite effects on glucose disposal and glucose-stimulated insulin secretion: a stable lable intravenous glucose tolerance test minimal model study. Diabetes 1996; 45:1373-1378.
102. Zeman RJ, Ludemann R, Easton TG. Slow to fast alterations in skeletal muscle fibers caused by clenbuterol, a beta-2-receptor antagonist. Am J Physiol 1988; 254:E726-E732.
103. Klein J, Fasshauer M, Ito M, Lowell BB, Benito M, Kahn CR. B3-adrenergic stimulation differentially inhibits insulin signaling and decreases insulin-induced glucose uptake in brown adipocytes. J Biol Chem 1999; 49:34795-34802.
104. Lillioja S, Young AA, Culter CL, Ivy JL, Abbott WG, Zawadzki JK, et al. Skeletal muscle capillary density and fibre type are possible determinants of in vivo insulin resistance in man. J Clin Invest 1987; 80:415-424.
105. Juhlin-Dannfelt A, Frisk-Holmberg F, Karlsson J, Tesch P. Central and peripheral circulation in relation to muscle-fibre composition in normo- and hypertensive man. Clin Sci 1979; 56:335-340.
106. Jamerson KA. Vasoconstriction with norepinephrine causes less forearm insulin resistance than reflex sympathetic vasoconstriction. Hypertension 1994; 23:813-817.
107. Masuo K, Mikami H, Ogihara T, Tuck ML. Sympathetic nerve hyperactivity precedes hyperinsulinemia and blood pressure elevation in a young, nonobese Japanese population. Am J Hypertens 1997; 10:77-83.
108. Pollare T, Lithell H, Morlin C, Prantare H, Hvarfner A, Ljunghall S. Metabolic effects of diltiazem and atenolol: results from a randomized, double-blind study with parallel groups. J Hypertens 1989; 7:551-559.
109. Pollare T, Lithell H, Selinius I. Application of prazosin is associated with an increase in insulin sensitivity in obese patients with hypertension. Diabetologia 1988; 31:415-420.
110. Haenni A, Lithell H. Treatment with beta-blocker with beta 2-agonism improves glucose and lipid metabolism in essential hypertension. Metabolism 1994; 43:455-461.
111. Meredith IT, Friberg P, Jennings GL, Dewar EM, Fazio VA, Lambert GW, Esler MD. Exercise training lowers resting renal but not cardiac sympathetic activity in humans. Hypertension 1991; 18:575-582.
112. O'Dea K, Esler M, Leonard P, Stockigt J, Nestel P. Noradrenaline turnover during under- and over-eating in normal weight subjects. Metabolism 1982; 31:896-899.
113. Perry IJ, Villegas R, Salim A, Flynn A. Clustering of protective factors for glucose intolerance and insulin resistance: a cross-sectional study. Diabet Med 2005; 22:1091-1097.
114. Messerli FH, Grossman E, Leonetti G. Antihypertensive therapy and new onset diabetes. J Hypertens 2004; 22:1845-1847.
115. Kaaja R, Manhem K, Tuomilehto J. Treatment of postmenopausal hypertension with moxonidine, a selective imidazoline receptor agonist. Int J Clin Pract 2003; 139:26-32.
116. Kohno K, Matsuoka H, Takenaka K, Miyake Y, Okuda S, Nomura G, Imaizumi T. Depressor effect by exercise training is associated with amelioration of hyperinsulinemia and sympathetic overactivity. Int Med 2000; 39:1013-1019.
117. Manzella D, Grella R, Esposito K, Giugliano D, Barbagallo M, Paolisso G. Blood pressure and cardiac autonomic nervous system in obese type 2 diabetic patients: effect of metformin administration. Am J Hypertens 2004; 17:223-227.
118. Yosefy C, Magen E, Kiselevich A, Priluk R, London D, Volchek L, Viskoper RJ Jr. Rosiglitazone improves, while Glibenglamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity. J Cardiovasc Pharmacol 2004; 44:215-222.
119. Haenni A, Lithell H. Moxonidine improves insulin sensitivity in insulin-resistant hypertensives. J Hypertens 1999; 17 (suppl 3):S29-S35.
120. Lender D, Arauz-Pacheco C, Breen L, Mora-Mora P, Ramirez LC, Raskin P. A double-blind comparison of the effects of amlodipine and enalapril on insulin sensitivity in hypertensive patients. Am J Hypertens 1999; 12:298-303.
121. Grassi G, Seravalle G, Dell Óro R, Trevano FO, Bombelli M, Scopelliti F, et al. Comparative effects of candesartan and hydrochlorthiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens 2003; 21:1761-1769.
122. Klein IH, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PL. Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic heart renal failure. J Am Soc Nephrol 2003; 14:425-430.
123. Jandeleit-Dahm AM, Tikellis C, Reid C, Johnston CI, Cooper ME. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 2005; 23:463-473.